Rhea-AI Summary
Sangamo Therapeutics, Inc. describes progress in its Chapter 11 case and its Nasdaq listing status. After filing for voluntary Chapter 11 relief on June 23, 2026, the Delaware bankruptcy court approved Bidding Procedures on July 14, 2026 for a potential sale of all or substantially all assets.
The order sets a bid deadline of August 4, 2026, a potential auction on August 10, 2026, and a sale hearing on August 20, 2026, while the company operates as a debtor-in-possession seeking to maximize stakeholder value. On the same date, a Nasdaq Hearings Panel denied continued listing, and the company expects Nasdaq to file Form 25 to complete delisting as its shares trade on the OTCID Basic Market under the symbol SGMOQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many SANGAMO THERAPEUTICS (SGMOQ) SEC filings are available on StockTitan?
StockTitan tracks 11 SEC filings for SANGAMO THERAPEUTICS (SGMOQ), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for SANGAMO THERAPEUTICS (SGMOQ)?
The most recent SEC filing for SANGAMO THERAPEUTICS (SGMOQ) was filed on July 20, 2026.